Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013

participating rights in any Excess Cash Dividend[2] of RMB0.08 ($0.01) for fiscal 2013.  Net cash provided by operating activities for full year of fiscal 2013 was RMB578.6  million ($93.2 million), up from RMB353.9 million in the prior year due to higher adoption rates regarding upfront payment option and the increase in new subscriber sign-ups.

Ms. Zheng stated, "Moving away from the Year of the Dragon and entering fiscal 2014, we expect to experience both challenges and opportunities.  As the Chinese market gradually resumes lower normalized birth trends, we anticipate some near-term pressure to subscriber growth rates.  Consequently, our near-term priority is to penetrate the Guangdong market by adding new storage capacity in the region and accelerating the development and renovation process with respect to the new Zhejiang storage facility." 

"As the Company is a premium cord blood banking operator, consistent with our pricing strategy to date and pursuit of high quality standings, we have decided to readjust our prices by increasing the processing fee to RMB6,800 from RMB5,800 and gross annual payment to RMB980 from RMB620 across Beijing municipality, Guangdong province and Zhejiang province.  This initiative will allow us to maximize profitability and offset rising production costs.  We remain dedicated to our China expansion strategy by deepening our penetration into our local territories while also pursuing new opportunities in other regions of China where we do not currently serve.  We continue to build on our favorable market position and industry trend to better serve the needs of our customers and drive improved performance for our shareholders." Ms. Zheng concluded.

[1] The terms of the convertible notes issued to KKR and Golden Meditech provide KKR and Golden Meditech with the ability to participate in any excess cash dividend. Therefore, the calculation of basic EPS has taken into cons
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. RAPS Opens Offices in Singapore and China
2. Research Report on Chinas Diabetes Drug Market, 2013-2017
3. Research Report on Chinas Antidepressant Market, 2013-2017
4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
11. China Cord Blood Corporation Received AABB Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... The Pistoia Alliance, a global, not-for-profit alliance of ... to innovation in R&D, has announced the start of ... Mapping project has been set up to create better ... life sciences R&D. The project will see the Pistoia ... services to enable the universal application of ontologies. , ...
(Date:4/28/2015)... 28, 2015 According to a 2013 ... patients receive medical treatment from burn injuries per year. ... injury, extensive formation of scars with subsequent contractures remains ... for which there is no adequate treatment. Contractures are ... movement and can cause permanent deformity. , Synedgen ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , ... battling infertility in this country, testified on behalf of ... first state in the nation to consider creating a clearinghouse ... who desire to receive them. , Infertility affects over 7.3 ... is one of the few medical diseases that is curable, ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... un nuevo receptor utilizando tecnología de descubrimiento de biomarcador ... en el tratamiento de millones de pacientes con cáncer ... que ha recibido una patente en Europa titulada "Tissue ... de Molecular Health de que EPHB4 es un nuevo ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... , ... ... ...
... March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), ... it has entered into two definitive license agreements with University ... in Toronto, Ontario , granting Trillium exclusive worldwide rights ... stem cell transplantation and cancer. , ...
... President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel . , ... , ... ... ...
Cached Biology Technology:Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference 2
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... by two Queens scientists has resulted in an exciting new ... chemical weapons and pesticides. Recently completed testing by an ... be greater than 99 per cent effective when used on ... tested in solution, full destruction of all three agents was ...
... genetic modification (GM) and RNA Interference are being deployed ... series of European and global initiatives. The ground was ... that exploit these technologies at a recent workshop organised ... highlighted the interlocking themes underlying the debate over livestock ...
... in molecular targeting, translational cancer research and cancer ... 17,000 scientists from around the world gather at ... the 2008 Annual Meeting of the American Association ... the meeting will include late-breaking clinical trial findings ...
Cached Biology News:Queen's develops safe 'green' decontamination method 2Europe develops new technologies to boost health of livestock 2Europe develops new technologies to boost health of livestock 3AACR annual meeting showcases developments in understanding and targeting cancers 2AACR annual meeting showcases developments in understanding and targeting cancers 3
...
...
...
Sold individually or included in the MasterAmp™ PCR Optimization Kit without ammonium sulfate. Includes dNTPs, buffer, and varying amounts of MgCl2 and the MasterAmp™ PCR Enhancer (with be...
Biology Products: